The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
about
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
The cost-effectiveness of UGT1 ...... an statutory health insurance.
@en
The cost-effectiveness of UGT1 ...... an statutory health insurance.
@nl
type
label
The cost-effectiveness of UGT1 ...... an statutory health insurance.
@en
The cost-effectiveness of UGT1 ...... an statutory health insurance.
@nl
prefLabel
The cost-effectiveness of UGT1 ...... an statutory health insurance.
@en
The cost-effectiveness of UGT1 ...... an statutory health insurance.
@nl
P2093
P2860
P1433
P1476
The cost-effectiveness of UGT1 ...... an statutory health insurance.
@en
P2093
Arne Pfeufer
Bettina Butzke
Clemens Giessen-Jung
Franziska Severin
Fuat S Oduncu
Volker Heinemann
Wolf H Rogowski
P2860
P304
P356
10.3109/0284186X.2015.1053983
P577
2015-06-22T00:00:00Z